Primary intestinal lymphoma in patients with inflammatory bowel disease: A descriptive series from the prebiologic therapy era

Inflammatory Bowel Diseases

Volumn 17, Issue 7, 2011, Pages 1557-1563

  Holubar, Stefan D ^a   Dozois, Eric J ^b   Loftus Jr , Edward V ^b   Teh, Swee H ^b   Benavente, Luis A ^b   Harmsen, W Scott ^b   Wolff, Bruce G ^b   Cima, Robert R ^b   Larson, David W ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

biologic therapy; Crohn's disease; gastrointestinal carcinogenesis; inflammatory bowel disease; infliximab; surgery lymphoma; ulcerative colitis

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOLOGICAL THERAPY; BLOODY DIARRHEA; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CROHN DISEASE; DUODENUM; ENTERITIS; FEMALE; HUMAN; ILEUM; INTESTINE LYMPHOMA; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMALL INTESTINE; STOMACH; SYMPTOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL THERAPY; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL NEOPLASMS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958863060     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21516     Document Type: Article

References (20)

1. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451-459. (Pubitemid 38182302)
2. Eaden JA, Abrams KR, Mayberry JF., The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48: 526-535. (Pubitemid 32234798)
3. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997; 337: 1029-1035.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476. (Pubitemid 41770166)
5. Zafar SY, Howell DN, Gockerman JP., Malignancy after solid organ transplantation: an overview. Oncologist. 2008; 13: 769-778.
6. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54: 1121-1125. (Pubitemid 41025906)
7. Loftus EV Jr, Sandborn WJ., Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. Gastroenterology. 2001; 121: 1239-1242. (Pubitemid 33022106)
8. Kumar S, Fend F, Quintanilla-Martinez L, et al. Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol. 2000; 24: 66-73. (Pubitemid 30033398)
9. Hall CH Jr, Shamma M., Primary intestinal lymphoma complicating Crohn's disease. J Clin Gastroenterol. 2003; 36: 332-336. (Pubitemid 36331616)
10. Nyam DC, Pemberton JH, Sandborn WJ, et al. Lymphoma of the pouch after ileal pouch-anal anastomosis: report of a case. Dis Colon Rectum. 1997; 40: 971-972. (Pubitemid 27355402)
11. Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991; 67: 2015-2019.
12. Karlen P, Lofberg R, Brostrom O, et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 1999; 94: 1047-1052. (Pubitemid 29173626)
13. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001; 121: 1080-1087. (Pubitemid 33022087)
14. Persson PG, Karlen P, Bernell O, et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology. 1994; 107: 1675-1679. (Pubitemid 24357620)
15. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005; 54: 617-622. (Pubitemid 40559243)
16. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91: 854-862. (Pubitemid 32173312)
17. Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000; 95: 2308-2312.
18. Palli D, Trallori G, Bagnoli S, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology. 2000; 119: 647-653.
19. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002; 122: 72-77. (Pubitemid 34049196)
20. Tondini C, Giardini R, Bozzetti F, et al. Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience. Ann Oncol. 1993; 4: 831-837. (Pubitemid 24032089)